4 completed, 2 unknown. 6 Phase 2, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 4, Unknown 2 |
| Phase 3 | 4 | Completed 2, Unknown 2 |
Follow ravidasvir: new trials by email Literature Review of ravidasvir trials Research Report on ravidasvir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 8- Versus 12-week of Sofosbuvir-ravidasvir Treatment of Chronic Hepatitis C Sofosbuvir 400 MG, Ravidasvir 200mg - Hepatitis C | Phase 2 / Phase 3 | Completed | Muhammad Radzi Abu Hassan | 322 | 2021-03-23 | 2025-03-13 |
| Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects. Ravidasvir, Danoprevir, Ritonavir - HCV | Phase 2 / Phase 3 | Completed | Ascletis Pharmaceuticals Co., Ltd. | 425 | 2017-07-01 | 2020-07-28 |
| Strategic Transformation of the Market of HCV Treatments sofosbuvir + ravidasvir - Hepatitis C | Phase 2 / Phase 3 | Unknown | Drugs for Neglected Diseases | 603 | 2016-09-01 | 2021-01-20 |
| Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC Taiwan Ravidasvir, Danoprevir, Ritonavir - Chronic Hepatitis C | Phase 2 | Completed | Ascletis Pharmaceuticals Co., Ltd. | 38 | 2015-08-01 | 2020-10-22 |
| A Study of the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4 ravidasvir hydrochloride, sofosbuvir, ribavirin - Chronic Hepatitis C | Phase 2 / Phase 3 | Unknown | Pharco Pharmaceuticals | 300 | 2015-01-01 | 2016-04-07 |
| Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C PPI-668, BI 207127 Dose 1, BI 207127 Dose 2 - Chronic Hepatitis C | Phase 2 | Completed | Presidio Pharmaceuticals, Inc. | 38 | 2013-05-01 | 2015-11-25 |
Hepatitis C, Chronic (3) · Hepatitis C (2) · Liver Diseases (1) · Virus Diseases (1)
Ascletis Pharmaceuticals Co., Ltd. (2) · Drugs for Neglected Diseases (1) · Muhammad Radzi Abu Hassan (1) · Pharco Pharmaceuticals (1) · Presidio Pharmaceuticals, Inc. (1)
Malaysia (2) · China (1) · Egypt (1) · Thailand (1) · United States (1)
Gamal Esmat, M.D. (1) · Huoling Tang, PhD (1) · Isabelle Andrieux-Meyer, MD (1) · Muhammad Radzi Abu Hassan, FRCP (1) · Nathaniel Brown, MD (1) · Satawat Thongsawat, MD (1) · Soek-Siam Tan, MD (1) · Yahong Chen, Master (1)